Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	167	$813.66	65,179
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	58	$814.06	65,121
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	155	$815.97	64,966
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	829	$816.46	64,137
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	1,881	$817.36	62,256
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	1,333	$818.59	60,923
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	973	$819.57	59,950
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	345	$820.54	59,605
Dec 05, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Open market or private sale of non-derivative or derivative security	184	$821.46	59,421
Dec 04, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	20,000	$270.43	79,421

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media